RPG Life Sciences says it is doubling down on its API business as the growth engine, while lining up a significant acquisition to expand capacity. The company also plans to enter the GLP-1 weight-loss therapy market by August-September, despite geopolitical risks. Its strategy centers on niche, complex molecules and moving into new therapy areas.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
